1. Japan Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Cytori Cell Research Institute, Inc.

Cytori Cell Research Institute, Inc.

3750.T
Cytori Cell Research Institute, Inc.JP flagTokyo
670.00
JPY
-6.00
(-0.89%)
16.63EPS
40.29P/E
5.98BMarket Cap
May 15Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription. 

Upgrade
Capital Structure

•

in mil. unless spec.
Working Capital

•

in mil. unless spec.
Growth Rates

•

in mil. unless spec.
Quarterly Revenue

•

in mil. unless spec.
Quarterly Earnings Per Share

•

in mil. unless spec.
Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO
Mr. Yoshihiro Hoshino
Full Time Employees
16
Sector
Healthcare
Industry
Biotechnology
Address
Otemachi Park Building, 1-1-1 Otemachi Tokyo Japan 100-0004
IPO Date
Jan 1, 2001
Website
cytori.co.jp
Similar Companies
Business
Cytori Cell Research Institute, Inc., engages in the research, development, production, and sale of cell therapy related medical devices in Japan. The company sells cell therapy kits, as well as engages in the research and development of cell therapy technology, etc. Its products pipeline includes ECCI-50 for the treatment of male stress urinary incontinence and liver cirrhosis; and Cyt-006 to prevent postoperative adhesion for primary rectal cancer. The company is also conducting clinical trials/research on cell therapy for a range of diseases and applications, including anterior cruciate ligament repair, bone repair, burn scars, chronic wound healing, critical limb ischemia, anal and Crohn's disease fistulas, erectile dysfunction, etc. It also invests in, owns, develops, leases, and manages real estate projects and hotels; and provides real estate brokerage services. The company was formerly known as FRACTALE Corporation. Cytori Cell Research Institute, Inc. was incorporated in 2004 and is headquartered in Tokyo, Japan.